Table 1 Platform comparison for targeted assay development for the 24-gene hypoxia signature.

From: Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma

 

TLDA

NanoString

Pass rate (prospective)

26/28 (93%)

27/28 (96%)

Pass rate (retrospective)*

10/12 (83%)

280/286 (98%)

Hypoxia high result

7/26 (27%)

12/26 (46%)

RNA input

250 ng, 27.5 ng/µl

100 ng, 20 ng/µl

Intra-assay correlation**

0.99 (low), 1.00 (high)

0.98 (low), 1.00 (high)

Inter-assay correlation***

0.99 (low), 0.99 (high)

0.99 (low), 1.00 (high)

Samples/run

4

12

Hands-on time/run

7 h

6 h

Total time/run

48 h

48 h

  1. *TLDA—pilot study using VORTEX-Biobank samples, NanoString—main validation studies using Manchester and VORTEX-Biobank cohorts.
  2. **Mean Spearman’s ρ for gene expression profiles for triplicate repeats in a single run for a low- and high-quality RNA sample.
  3. ***Mean Spearman’s ρ for gene expression profiles for triplicate/quadruplicate repeats across runs for a low- and high-quality RNA sample.
Back to article page